A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea
In 2010, Korea introduced 10-valent pneumococcal conjugate vaccine for children aged 6 weeks to 5 years against invasive disease caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and cross-reactive 19A. The aim of this 6-year real-world study of 646 healthy Korean c...
Saved in:
Main Authors: | Soon Min Lee (Author), Jang Hoon Lee (Author), Eun Song Song (Author), Sung Jin Kim (Author), Joon Hyung Kim (Author), Rupert W. Jakes (Author), Raghavendra Devadiga (Author), Moon Sung Park (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2018-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
by: Sven Arne Silfverdal, et al.
Published: (2017) -
Primary vaccination with the 10-valent pneumococcal non-typeable <it>Haemophilus influenzae </it>protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial
by: Dicko Alassane, et al.
Published: (2011) -
Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial
by: Shabir A Madhi, et al.
Published: (2017) -
Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea
by: Xu-Hao Zhang, et al.
Published: (2018) -
Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience
by: Tomas Mrkvan, et al.
Published: (2018)